IBI is developing a broad portfolio of clinically superior proprietary products, based on its Verisome® drug delivery technology. The company’s initial focus is on its pipeline of reduced-risk, low-cost development programs targeting every major ophthalmic market. IBI’s lead portfolio product, IBI-10090 completed enrollment in its pivotal phase 2/3 clinical trial, in December 2012. An NDA is planned for late 2013.
Two (2) additional products are scheduled to begin human clinical trials in 2013 including IBI-60089 for glaucoma and a second generation cataract inflammation/antibiotic product.
In November, 2012 IBI received FDA approval for its Orphan Drug Designation for IBI-80090 (melphalan for intraocular injection) for the treatment of retinoblastoma. IBI will be collaborating with Memorial Sloan Kettering Cancer Center on this project.